Latest Pharmaceuticals News

Page 10 of 89
Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.
Ada Torres
Ada Torres
31 Aug 2026
Alpha HPA Limited reported a 135% revenue increase but a 31% rise in net loss for FY2026, while progressing its Stage Two facility on schedule with robust customer demand exceeding 12,000 tonnes per annum under letters of intent.
Maxwell Dee
Maxwell Dee
31 Aug 2026
Thorney Technologies Ltd posted a $16.4 million net loss for FY2026, deepening from last year, as it continued to simplify its portfolio and execute a substantial share buyback program.
Victor Sage
Victor Sage
28 Aug 2026
Castile Resources reveals a robust 2026 Scoping Study for its Rover 1 IOCG Project, projecting an 11-year underground mine life with five valuable metals driving strong economics and a staged development strategy.
Maxwell Dee
Maxwell Dee
28 Aug 2026
Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.
Ada Torres
Ada Torres
28 Aug 2026
Australian Foundation Investment Company (ASX:AFI) reported a $293.5 million profit for FY26, holding dividends steady despite portfolio returns lagging the market. Leadership transitioned as Alison Gibson took the helm following Mark Freeman’s retirement.
Claire Turing
Claire Turing
28 Aug 2026
Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.
Ada Torres
Ada Torres
28 Aug 2026
ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.
Ada Torres
Ada Torres
28 Aug 2026
LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.
Ada Torres
Ada Torres
28 Aug 2026
Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.
Ada Torres
Ada Torres
27 Aug 2026
Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.
Ada Torres
Ada Torres
27 Aug 2026
Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
Victor Sage
27 Aug 2026

Browse the archive

Full archive